Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Javier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, Adrián Neyra, Pedro Iborra, Luis Gutiérrez-Rojas & Selman F. Salonia. (2022) Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opinion on Drug Safety 21:5, pages 673-690.
Read now
Read now
Reiji Yoshimura, Atsuko Ikenouchi, Naomichi Okamoto & Yuki Konishi. (2021) A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine. International Medical Case Reports Journal 14, pages 271-273.
Read now
Read now
Giulia Perini, Matteo Cotta Ramusino, Elena Sinforiani, Sara Bernini, Roberto Petrachi & Alfredo Costa. (2019) Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatric Disease and Treatment 15, pages 1249-1258.
Read now
Read now
Marc Kelliny, Paul E Croarkin, Katherine M Moore & William V Bobo. (2015) Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management 11, pages 1193-1212.
Read now
Read now
Alan L Pehrson & Connie Sanchez. (2015) Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Design, Development and Therapy 9, pages 603-624.
Read now
Read now
Mayce Al-Sukhni, Nadia A Maruschak & Roger S McIntyre. (2015) Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opinion on Drug Safety 14:8, pages 1291-1304.
Read now
Read now
Articles from other publishers (43)
Jolanta Jaśkowska, Anna Karolina Drabczyk, Paweł Śliwa, Przemysław Jodłowski, Edyta Pindelska, Damian Kułaga, Przemysław Zaręba, Zbigniew Majka, Agata Siwek, Małgorzata Wolak & Marcin Kołaczkowski. (2023) Ultrasound assisted one-pot synthesis and preliminary in vitro studies of salicylamide arylpiperazines as dual 5-HT1A/5-HT7 ligands. Journal of Molecular Structure 1275, pages 134585.
Crossref
Crossref
Sergio De Filippis, Ginevra Lombardozzi, Marta Matrone, Emanuela Amici, Giada Trovini, Filippo Perrini, Alessandro Di Giovanni, Valeria Giovanetti & Georgios D. Kotzalidis. (2022) Differential Response to Three Antidepressants in Patients with Major
Depressive Episode Who Suffered Covid-19-Related Trauma. Current Neuropharmacology 20:12, pages 2393-2407.
Crossref
Crossref
A. Alcántara Montero & S.R. Pacheco de Vasconcelos. (2022) Role of vortioxetine in the treatment of neuropathic pain. Revista Española de Anestesiología y Reanimación (English Edition) 69:10, pages 640-648.
Crossref
Crossref
A. Alcántara Montero & S.R. Pacheco de Vasconcelos. (2022) Papel de vortioxetina en el tratamiento del dolor neuropático. Revista Española de Anestesiología y Reanimación 69:10, pages 640-648.
Crossref
Crossref
Susana Barbosa-Méndez, Gilberto Perez-Sánchez & Alberto Salazar-Juárez. (2022) Vortioxetine treatment decreases cocaine-induced locomotor sensitization in rats. Physiology & Behavior 257, pages 113989.
Crossref
Crossref
Simeon Shalom Feinberg. (2021) Poor man’s vortioxetine. CNS Spectrums 27:5, pages 541-542.
Crossref
Crossref
Paula Alina Fotache, Liliana Mititelu-Tartau, Maria Bogdan, Beatrice Rozalina Buca, Liliana Lacramioara Pavel, Ana-Maria Pelin, Andreea-Daniela Meca, Cosmin-Gabriel Tartau & Gratiela Eliza Popa. (2022) Magnesium Potentiates the Vortioxetine’s Effects on Physical Performances and Biological Changes in Exercise-Induced Stress in Rats. Medicina 58:10, pages 1363.
Crossref
Crossref
Hung-Tsung Hsiao, Jeffrey Chi-Fei Wang & Sheng-Nan Wu. (2022) Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant. Biomedicines 10:6, pages 1318.
Crossref
Crossref
Reiji Yoshimura, Naomichi Okamoto, Yuki Konishi & Atsuko Ikenouchi. (2021) Major depression with musical obsession treated with vortioxetine: a case report. Annals of General Psychiatry 20:1.
Crossref
Crossref
Kendall MarshallPalika DattaKathleen Rewers-FelkinsKaytlin KrutschTeresa BakerThomas W. Hale. (2021) Transfer of the Serotonin Modulator Vortioxetine into Human Milk: A Case Series. Breastfeeding Medicine 16:10, pages 843-845.
Crossref
Crossref
Alexei Verkhratsky, Vladimir Parpura, Caterina Scuderi & Baoman Li. 2021. Astrocytes in Psychiatric Disorders. Astrocytes in Psychiatric Disorders
317
347
.
Roshan Sutar, Faisal Siddiqui & Abin Rajan. (2020) Is Vortioxetine an Advantageous Choice for Erectile Dysfunction? A Case Report. Journal of Psychosexual Health 2:3-4, pages 281-283.
Crossref
Crossref
Patrick McLaughlin & Anthony Cleare. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
227
267
.
Ruth Madden Foreman, Michelle Zappas & Candice Whitely. (2020) Antidepressant Withdrawal: A Guide for Primary Care Clinicians. The Journal for Nurse Practitioners 16:3, pages 191-194.
Crossref
Crossref
James D. Sexton, Charles D. Nichols & Peter S. Hendricks. (2020) Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. Frontiers in Psychiatry 10.
Crossref
Crossref
Hao Geng, Dangwei Peng, Yuanyuan Huang, Dongdong Tang, Jingjing Gao, Yao Zhang & Xiansheng Zhang. (2019) Changes in sexual performance and biochemical characterisation of functional neural regions: A study in serotonin transporter knockout male rats. Andrologia 51:7.
Crossref
Crossref
Gustavo Roberto Villas Boas, Roseli Boerngen de Lacerda, Marina Meirelles Paes, Priscila Gubert, Wagner Luis da Cruz Almeida, Vanessa Cristina Rescia, Pablinny Moreira Galdino de Carvalho, Adryano Augustto Valladao de Carvalho & Silvia Aparecida Oesterreich. (2019) Molecular aspects of depression: A review from neurobiology to treatment. European Journal of Pharmacology 851, pages 99-121.
Crossref
Crossref
Jovana Vojvodic, Goran Mihajlovic, Ana Andonov, Milos Markovic, Jelena Djordjevic & Petar Vojvodic. (2019) Immunological Aspects of Depressive Disorder – The Review. Serbian Journal of Experimental and Clinical Research 0:0.
Crossref
Crossref
Derek Spieler, Christian Namendorf, Tamara Namendorf & Manfred Uhr. (2019) abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. Journal of Psychiatric Research 109, pages 48-51.
Crossref
Crossref
Imon Paul. (2018) Newer Updates in Psychiatry: Focus on Vortioxetine. Indian Journal of Private Psychiatry 12:2, pages 62-65.
Crossref
Crossref
Dasiel Borroto-Escuela, Manuel Narváez, Patrizia Ambrogini, Luca Ferraro, Ismel Brito, Wilber Romero-Fernandez, Yuniesky Andrade-Talavera, Antonio Flores-Burgess, Carmelo Millon, Belen Gago, Jose Narvaez, Yuji Odagaki, Miklos Palkovits, Zaida Diaz-Cabiale & Kjell Fuxe. (2018) Receptor–Receptor Interactions in Multiple 5-HT1A Heteroreceptor Complexes in Raphe-Hippocampal 5-HT Transmission and Their Relevance for Depression and Its Treatment. Molecules 23:6, pages 1341.
Crossref
Crossref
Anita H. Clayton & Linda Vignozzi. 2018. Textbook of Female Sexual Function and Dysfunction. Textbook of Female Sexual Function and Dysfunction
59
100
.
Anna Rita Zuena, Daniela Maftei, Giovanni Sebastiano Alemà, Francesca Dal Moro, Roberta Lattanzi, Paola Casolini & Ferdinando Nicoletti. (2018) Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Molecular Pain 14, pages 174480691880898.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 11:1, pages 48-59.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. Revista de Psiquiatría y Salud Mental 11:1, pages 48-59.
Crossref
Crossref
Pablo D. Pérez, Zhiwei Ma, Christina Hamilton, Connie Sánchez, Arne Mørk, Alan L. Pehrson, Christoffer Bundgaard & Nanyin Zhang. (2018) Acute effects of vortioxetine and duloxetine on resting-state functional connectivity in the awake rat. Neuropharmacology 128, pages 379-387.
Crossref
Crossref
M. Oppa, I. Ondrejka, D. Cesnekova, I. Tonhajzerova & G. Nosalova. (2017) Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results. European Pharmaceutical Journal 64:1, pages 13-16.
Crossref
Crossref
Kinga Ostrowska, Katarzyna Młodzikowska, Monika Głuch-Lutwin, Anna Gryboś & Agata Siwek. (2017) Synthesis of a new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT 1A affinities. European Journal of Medicinal Chemistry 137, pages 108-116.
Crossref
Crossref
James E. Frampton. (2016) Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 76:17, pages 1675-1682.
Crossref
Crossref
M. Oppa, T. Kulhan, G. Nosáľová & I. Ondrejka. (2016) Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine. European Pharmaceutical Journal 63:1, pages 25-28.
Crossref
Crossref
M Oppa, D Cesnekova, G Nosalova & I Ondrejka. (2016) Review of a New Multimodal Antidepressant Vortioxetine. Acta Medica Martiniana 16:2, pages 44-48.
Crossref
Crossref
Deepali Gupta, Visakh Prabhakar & Mahesh Radhakrishnan. (2016) 5HT3 receptors: Target for new antidepressant drugs. Neuroscience & Biobehavioral Reviews 64, pages 311-325.
Crossref
Crossref
Christoffer Bundgaard, Elin Eneberg & Connie Sánchez. (2016) P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo. Neuropharmacology 103, pages 104-111.
Crossref
Crossref
Dasiel O. Borroto-Escuela, Alexander O. Tarakanov & Kjell Fuxe. (2016) FGFR1–5-HT1A Heteroreceptor Complexes: Implications for Understanding and Treating Major Depression. Trends in Neurosciences 39:1, pages 5-15.
Crossref
Crossref
Lei Liu, Na Cao, Xingling Ma, Kaihe Xiong, Lili Sun, Qiaogen Zou & Lili Yao. (2016) Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC–MS, IR and NMR. Journal of Pharmaceutical and Biomedical Analysis 117, pages 325-332.
Crossref
Crossref
Angel L. Montejo, Laura Montejo & Felipe Navarro-Cremades. (2015) Sexual side-effects of antidepressant and antipsychotic drugs. Current Opinion in Psychiatry 28:6, pages 418-423.
Crossref
Crossref
Er-min Gu, Chengke Huang, Bingqing Liang, Lingjing Yuan, Tian Lan, Guoxin Hu & Hongyu Zhou. (2015) An UPLC–MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Journal of Chromatography B 997, pages 70-74.
Crossref
Crossref
Mostafa El Mansari, Maurice Lecours & Pierre Blier. (2015) Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology 232:13, pages 2343-2352.
Crossref
Crossref
Anthony Cleare, CM Pariante, AH Young, IM Anderson, D Christmas, PJ Cowen, C Dickens, IN Ferrier, J Geddes, S Gilbody, PM Haddad, C Katona, G Lewis, A Malizia, RH McAllister-Williams, P Ramchandani, J Scott, D Taylor & R Uher. (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 29:5, pages 459-525.
Crossref
Crossref
Cristóbal Gastó, Joana Guarch & Víctor Navarro. (2015) Dominios cognitivos en la depresión unipolar. Teorías multimodales y nuevas perspectivas terapéuticas. Psiquiatría Biológica 22:2, pages 33-38.
Crossref
Crossref
Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg & Sven Ove Ögren. (2015) Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology 25:5, pages 599-656.
Crossref
Crossref
Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu & Maria Francesca Moro. (2015) Depression and Cerebrovascular Disease: Could Vortioxetine Represent a Valid Treatment Option?. Clinical Practice & Epidemiology in Mental Health 11:1, pages 144-149.
Crossref
Crossref
Ahmet Özdemir, Mehlika Altıntop, Zafer Kaplancıklı, Özgür Can, Ümide Demir Özkay & Gülhan Turan-Zitouni. (2015) Synthesis and Evaluation of New 1,5-Diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole Derivatives as Potential Antidepressant Agents. Molecules 20:2, pages 2668-2684.
Crossref
Crossref